<http://webisa.webdatacommons.org/70974232>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/70974232>	<http://www.w3.org/ns/prov#value>	"discontinued due to AEs during weeks 0 to 12.Patients with relapsing forms of MS who transitioned from original-formulation subcutaneous" .
<http://webisa.webdatacommons.org/70974232>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<unboundmedicine.com> .
<http://webisa.webdatacommons.org/prov/124451442>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/70974232> .